Bellicum Pharma (BLCM) Reports Data Presentation Demonstrating Improved Immune Recovery Following … – StreetInsider.com
|
Bellicum Pharma (BLCM) Reports Data Presentation Demonstrating Improved Immune Recovery Following …
StreetInsider.com Patients were treated with BPX-501 following an alpha/beta T cell and CD19+ B cell depleted haploidentical hematopoietic stem cell transplant (haplo-HSCT). Results demonstrated that donor BPX-501 cells infused after transplant expanded in vivo and … |
